ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Inclusion Criteria:

   - Histologically confirmed locally advanced or metastatic undifferentiated pleomorphic
   sarcoma (UPS) or grade ≥ 2 myxofibrosarcoma (MFS)

   - Documented progression following systemic chemotherapy

   - At least one measurable lesion

   - Eastern Cooperative Oncology Group performance status of 0 or 1

   - Adequate hematologic and organ function

Exclusion Criteria:

   - More than two prior lines of chemotherapy for UPS/MFS

   - Prior immune checkpoint inhibitor or immunomodulatory therapy

   - Active autoimmune disease that has required systemic treatment

   - Major surgery within 4 weeks of dosing of investigational agent

   - Active additional malignancy

   - Pericardial effusion, pleural effusion, or ascites

   - Central nervous system metastases and/or carcinomatous meningitis

   - Active hepatitis or cirrhosis

   - Interstitial lung disease

   - Unwilling to apply highly effective contraception during the study

   - Other concurrent severe and/or uncontrolled medical conditions that would, in the
   investigator's judgment, contraindicate patient participation in the clinical study